Template File: /srv/users/serverpilot/apps/emquire/public/wp-content/themes/emquire2017/single-project.php | Template Hierarchy
WP version: 5.3.2
PHP version 7.1.33
Comparison of the improved oxygenation achieved by three different O2 flow rates using oxygen delivered by nasal high flow therapy in patients with acute respiratory failure receiving low, medium or high conventional oxygen therapy.
Oxygen delivered by nasal high flow therapy (HFNO2) is gaining prominence as a therapy for respiratory support in critically ill patients. In contrast to low flow oxygen devices e.g. the simple face mask or venturi mask, high flow nasal devices are able to deliver flow rates of up to 60 litres/minute. There is less entrainment of room air resulting in an inspired oxygen concentration (FiO2) delivered that is equal to that set on the device. High flow nasal oxygen is also well tolerated as inspired gas is warmed to 37°C and completely humidified which preserves mucociliary function. High flow nasal oxygen has been shown to generate of low levels of positive pressure in the upper airways which reduces alveolar collapse and increases lung volume. Improved efficiency of respiratory effort and decreased work of breathing result from a reduction in respiratory dead space and flushing out of carbon dioxide from the upper airway
The aim of this study is to determine in patients with different severities of respiratory failure, and using HFNO2, the FiO2 required to maintain low normal oxygen saturations and a respiratory rate that is not excessively high.
Central Line setup and documentation https://emquire.care/project/central-line-qi-project/ Neuroprotection bundles coming soon
OCTS (Outcomes following Chest Trauma Score) has begun in the QEUH ED! This study aims to measure patient reported outcomes following rib fractures to optimise and improve care of this patient group. The patient will be asked to fill in a questionnaire at time of injury and two follow up questionnaires to assess how […]
Nicola was our first nurse appointed smashing the interview and rapidly getting a handle on the intricacies of clinical research in the ED. Her portfolio of studies includes She leads on Rapid-CTCA, Target-CTCA, SABER and Pro Teds
Mark was appointed in June 2017 and has rapidly found his feet helping promote QEUH ED nurse engagement. His infectious enthusiasm and energy will be a huge asset to the team! He leads on Novel, Aerogen, RAMPP, Frontiers
Introducing Dave the Trauma Man! The QEUH will become a Major Trauma Centre in 2019 as part of the Scottish Trauma Network. Dave is going to have a pretty tough year… in fact he is going to experience more car accidents, falls from height and industrial accidents than any other manikin in Scotland.